Saturday 17 October 2026 Export HYFT’s income statement to Excel — free account

MindWalk Holdings Corp.

MindWalk Holdings Corp.’s revenue for fiscal 2026 (year ended April 2026) was $11.3 million, down 35.9% from fiscal 2025. In the quarter to July 2026, revenue grew 19.4%, EPS fell 80.0%, free cash flow grew 9.79% and total debt fell 10.8%, each against the same quarter a year earlier.

1.31 0.09 −6.43%

Follow HYFT

Alert me

Market cap: $66.0M
P/E: 0.0×
Fwd P/E: −9.0×
Dividend yield: —
F-score: 6/9
Altman Z: −5.59
Beneish M: −3.70
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 8.86%

Capital & Financial Ratios $m

Market Cap 65.95

Revenue 11.72

Net Income (12.31)

Free Cash Flow (9.00)

Net Debt (3.31)

Current Ratio 1.84

Debt/Equity 0.43

P/E ratio 0.00

Fwd P/E (9.01)

P/S ratio 5.23

P/B ratio 12.39

Past 5Y EPS Growth —

This Y EPS Growth (24.24%)

Next Y EPS Growth 14.00%

Next Y revenue growth 9.69%

Next 5Y EPS Growth 3.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 48.80%

10-year low 10-year high

P/B against its own 10 years 97.05%

10-year low 10-year high

EV/Sales against its own 10 years 55.82%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	3	8	8	5
Receivables	3	3	2	2
Inventory	2	2	0	0
Other	0	0	0	1
	9	13	12	9

	2024	2025	2026	Q'26
Payables	3	4	3	4
ST’ Debt	—	—	—	—
Other	0	0	—	—
	6	6	4	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	(3.83%)	(10.16%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(27.85%)	(41.94%)

Revenue $m

	Jul	Oct	Jan	Apr	Year
’26	3	—	—	—	—
’26	2	3	3	3	11
’25	4	4	4	5	18
’24	4	5	5	5	18
’23	4	4	4	4	16
’22	4	4	4	4	15
’21	3	4	4	4	14

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jul	Oct	Jan	Apr	Year
’26	(3)	—	—	—	—
’26	(3)	(2)	(2)	(2)	(9)
’25	(1)	(2)	(1)	(1)	(5)
’24	(1)	0	0	(2)	(3)
’23	(8)	(3)	(3)	(2)	(15)
’22	(1)	(2)	(4)	(1)	(8)
’21	0	0	(1)	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jul	Oct	Jan	Apr	Year
’26	(3)	—	—	—	—
’26	(3)	(2)	(2)	(2)	(9)
’25	(2)	(2)	(1)	(1)	(5)
’24	(1)	0	0	(3)	(4)
’23	(8)	(3)	(3)	(2)	(16)
’22	(1)	(2)	(5)	(2)	(9)
’21	0	0	(1)	(2)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Jul	Oct	Jan	Apr	Year
’26	(0.09)	—	—	—	—
’26	(0.05)	(0.05)	(0.06)	(0.06)	(0.22)
’25	(0.11)	(0.07)	(0.46)	(0.04)	(0.65)
’24	(0.11)	(0.07)	(0.08)	(0.52)	(0.78)
’23	(0.30)	(0.23)	(0.14)	(0.15)	(0.81)
’22	(0.14)	(0.21)	(0.16)	(0.17)	(0.67)
’21	(0.03)	(0.02)	(0.06)	(0.23)	(0.34)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	1.88	1.32	1.65	1.15	5.03	3.51	0.94	0.33	0.27	0.99	Analyst estimates 2027–2029 Powerpack
	High	5.94	5.05	3.17	33.34	19.00	6.79	5.60	2.60	3.25	2.99
People
People	Employees	—	—	—	—	73	85	102	101	102	77
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.19	0.18	0.15	0.18	0.17	0.15
Income, $m
Income, $m	Revenue	2	3	6	8	14	15	16	18	18	11
	Gross margin, %	27.33	(23.62)	(16.92)	(3.92)	64.41	56.72	55.95	49.16	55.25	58.80
	EBT	(4)	(3)	(4)	(3)	(5)	(13)	(21)	(21)	(25)	(11)
	EBT margin, %	(207.80)	(93.02)	(69.67)	(37.65)	(33.47)	(81.84)	(134.29)	(117.07)	(139.75)	(99.96)
	Net income	0	(3)	(4)	(3)	(6)	(13)	(20)	(20)	(22)	(10)
	Depreciation	0	0	1	2	3	3	5	4	4	1
Per share, $
Per share, $	Revenue	0.49	0.36	0.49	0.56	0.83	0.78	0.62	0.71	0.53	0.24
	Earnings	(0.99)	(0.33)	(0.34)	(0.19)	(0.34)	(0.67)	(0.81)	(0.78)	(0.65)	(0.22)
	Cash flow	(0.14)	(0.23)	(0.14)	(0.05)	(0.03)	(0.40)	(0.60)	(0.12)	(0.14)	(0.19)
	Capex	0.00	0.00	0.00	0.00	(0.06)	(0.05)	(0.05)	(0.04)	(0.02)	(0.01)
	Free cash flow	(0.14)	(0.23)	(0.14)	(0.05)	(0.09)	(0.45)	(0.64)	(0.16)	(0.15)	(0.20)
	Book value	0.57	0.84	0.80	0.57	2.64	3.05	1.75	0.98	0.51	0.18
	Shares, m	4	9	13	14	16	20	25	26	33	46
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	0.00	0.00	12.29	7.05	4.12	1.81	0.84	4.90
	P/B	0.00	0.00	0.00	0.00	3.89	1.81	1.47	1.31	0.87	6.48
	EV/Sales	0.00	0.00	0.00	0.00	10.16	5.59	4.05	2.19	1.00	4.56
	EV/FCF	0.00	0.00	0.00	0.00	(365.48)	(9.86)	(3.93)	(9.50)	(3.40)	(5.52)
Cash, $m
Cash, $m	Operating cash flow	(1)	(2)	(2)	(1)	0	(8)	(15)	(3)	(5)	(9)
	Capex	0	0	0	0	(1)	(1)	(1)	(1)	(1)	0
	Free cash flow	(1)	(2)	(2)	(1)	(2)	(9)	(16)	(4)	(5)	(9)
Balance, $m
Balance, $m	Working capital	2	0	1	0	33	22	8	2	7	8
	Total debt	—	2	2	2	3	1	5	9	8	2
	Net debt	(2)	1	(1)	1	(29)	(23)	(2)	6	1	(6)
	Shareholders’ equity	2	8	10	8	44	60	43	25	17	9
Returns, %
Returns, %	ROA	(61,796.48)	(42.17)	(28.16)	(17.81)	(17.19)	(21.18)	(30.03)	(39.09)	(56.85)	(42.67)
	ROIC	0.00	0.00	0.00	0.00	(23.94)	(21.62)	(32.05)	(20.69)	(31.55)	(269.05)
	ROE	(381.82)	(63.01)	(48.75)	(29.87)	(21.87)	(25.72)	(38.62)	(58.67)	(103.12)	(79.38)

Negative figures in brackets.

All 10 years →

Fiscal years to Apr 2026 · latest quarter Jul 2026 · fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CSBR Champions Oncology, Inc.	$66.7M	— (loss-making)	— (loss-making)	+8.84% (above 0%: growing)	n/m	−198.74% (below 0%: shrinking)	50.54%	(2.69%)	Compare
OSTX OS Therapies Incorporated	$66.0M	— (loss-making)	—	—	n/m	−134.43% (below 0%: shrinking)	—	0.00%	Compare
HYFT MindWalk Holdings Corp.	$66.0M	— (loss-making)	— (loss-making)	+19.37% (above 0%: growing)	n/m	+9.79% (above 0%: growing)	58.58%	(159.86%)
NMAD Nomad Power Solutions, Inc.	$65.9M	— (loss-making)	—	—	n/m	−230.63% (below 0%: shrinking)	—	0.00%	Compare
XBIT XBiotech Inc.	$65.9M	— (loss-making)	— (loss-making)	−93.33% (below 0%: shrinking)	n/m	+25.25% (above 0%: growing)	0.00%	0.00%	Compare
SPRO Spero Therapeutics, Inc.	$65.8M	7.9×	4.2×	−95.61% (below 0%: shrinking)	n/m	+69.73% (above 0%: growing)	100.00%	0.00%	Compare
VRCA Verrica Pharmaceuticals Inc.	$64.9M	— (loss-making)	— (loss-making)	−53.85% (below 0%: shrinking)	n/m	+7.63% (above 0%: growing)	85.02%	(223.42%)	Compare
CING Cingulate Inc.	$63.8M	— (loss-making)	—	—	n/m	−24.28% (below 0%: shrinking)	0.00%	0.00%	Compare
FBIO Fortress Biotech, Inc.	$63.7M	0.6×	1.1×	+14.04% (above 0%: growing)	n/m	−115.37% (below 0%: shrinking)	67.18%	(53.46%)	Compare
Median of peers	$65.8M	—	—	−53.85%	—	−69.82%	58.86%	0.00%

All 614 Biotechnology stocks →

MindWalk Holdings Corp. (HYFT) key facts

Concern: MindWalk Holdings Corp.’s revenue for fiscal 2026 (year ended April 2026) was $11.3 million, down 35.9% from fiscal 2025.
Concern: MindWalk Holdings Corp. reported a net loss of $10.1 million, or a loss of $0.22 per share, for fiscal 2026.
MindWalk Holdings Corp. (HYFT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, HYFT traded at $1.31, a market capitalization of $66.0 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 5.2× sales.
Return on equity was −79.4% and debt-to-equity 0.43.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −5.59 (distress zone) for fiscal 2026.